Medical professional administering a vaccine into a patient's arm

Who would first benefit from a Covid-19 vaccine?

It’s proven a challenging year so far in 2020, particularly as a result of Covid-19, so news that a potential vaccine candidate has shown promising results has been greeted with a significant sense of optimism. But, should the vaccine meet the remaining criteria and be approved for use, who would benefit first from it?

Well, at least here in the UK, the biggest risk factor for contracting and developing severe and potentially fatal Covid-19 cases has been identified as within the care home sector.

Particularly among older care home residents, the risk of serious ill health as a result of Covid-19 is significantly heightened.

As such, it is expected that elderly care home residents and the staff looking after them would be top of any preliminary priority list for a vaccine.

This would be closely followed by health workers, such as hospital staff.

Within the wider population, people are likely to be ranked by age – with those who are identified as healthy, with minimal risk and under the age of 50 towards the bottom of the list. This is due to a lower risk of serious Covid-19 infection than those over the age of 50 or with existing health complications, two severely at-risk groups who have accounted for a significant proportion of the deaths from the virus in the UK to date.

Initial optimism has been followed by suggestions that, should all remaining processes go smoothly, the first vaccinations could take place even before Christmas. There remains a number of notable hurdles to overcome though, particularly logistically when it comes to vaccinating the wider population.

It is expected the vaccine will be delivered through care homes, GPs and pharmacists, as well as the establishing of a network of “go-to” vaccination centres set up in sports halls and such facilities.

However, transportation and storage of the vaccine could prove challenging initially.

With requirements to be stored at minus 80C, the vaccine needs to remain in a process called cold chain storage – whereby it remains in a temperature-controlled supply chain.

An unbroken cold chain refers to an uninterrupted series of refrigerated production, storage and distribution activities to guarantee the vaccine is kept continually at the desired low-temperature range and it remains as effective as intended.

The UK has some cold chain capabilities, with NHS sites well-equipped, but at present it will remain out of reach of many local GP surgeries and makeshift vaccination centres without notable investment and financial support from Government.

NHE March/April 2024

NHE March/April 2024

A window into the past, present and future of healthcare leadership.

- Steve Gulati, University of Birmingham 

More articles...

View all
Online Conference

Presenting

2024 Online Conferences

In partnership with our community of health sector leaders responsible for delivering the UK's health strategy across the NHS and the wider health sector, we’ve devised a collaborative calendar of conferences and events for industry leaders to listen, learn and collaborate through engaging and immersive conversation. 

All our conferences are CPD accredited, which means you can gain points to advance your career by attending our online conferences. Also, the contents are available on demand so you can re-watch at your convenience.

National Health Executive Podcast

Ep 42. Leadership in the NHS

In episode 42 of the National Health Executive podcast we were joined by Steve Gulati who is an associate professor at the University of Birmingham as well as director of healthcare leadership at the university’s Health Services Management Centre.